- Home
- NCV vs AVTX Comparison
NCV vs AVTX Comparison
Compare NCV & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCV | AVTX |
|---|---|---|
| Founded | 2003 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.8M | 339.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | NCV | AVTX |
|---|---|---|
| Price | $14.96 | $13.23 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $32.57 |
| AVG Volume (30 Days) | 85.3K | ★ 585.6K |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 12.48% | N/A |
| EPS Growth | N/A | ★ 81.66 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $11.51 | $3.39 |
| 52 Week High | $16.70 | $20.72 |
Technical Indicators
Market Signals| Indicator | NCV | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 31.23 | 32.45 |
| Support Level | $14.84 | $8.87 |
| Resistance Level | $15.65 | $16.40 |
| Average True Range (ATR) | 0.31 | 1.12 |
| MACD | -0.06 | -0.45 |
| Stochastic Oscillator | 5.59 | 1.10 |
Price Performance
Historical ComparisonAbout NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).